DONATE TODAY
To Increase Patient Access

The Next Generation of Cellular Therapies

Current Clinical Trial Information

If you or a family member are interested in participating in this clinical trial or would like to gather additional information about it, EBCI is here to assist you in connecting with the Principal Investigators or research facilities located near you. Please feel free to get in touch with Shreya Prakash by clicking the "Interest Form" button above,  emailing her at shreya@endbraincancer.org or calling/texting 425-436-8688.

Study Overview

NCT05664243
Contact: Trishna Goswami, MD
1-646-933-5607 
INB-400@in8bio.com
Backup Contact: Stacey Bilinski
1-646-933-5607 
INB-400@in8bio.com

Official Title:
A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma.

Brief Summary:
This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.
Kentucky Location:
RECRUITING
University of Louisville Hosptial
James Graham Brown Cancer Center.

Alabama Location:
NOT YET RECRUITING
University of Alabama in Birmingham

The IN8bio Mission
IN8bio was founded with the mission of developing novel therapies to address cancer. The company focuses on the development of cellular therapies using gamma-delta T cells, the “unconventional” T cell and is advancing a pipeline of autologous, allogeneic and genetically modified product candidates for both liquid and solid tumors.
We are the first company to advance genetically modified gamma-delta T cells into the clinic, leveraging the powerful and naturally occurring anti-cancer properties of these cells to enable their use in combination with therapeutic administration of chemotherapy.

Our Pipeline

Our Preclinical and Clinical Programs

A Novel Approach to Cancer Cell Therapy

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Our platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. We are one of the most advanced gamma-delta T cell companies and the first to bring genetically modified gamma-delta T cells into the clinic. Our lead product candidates are currently in Phase 1 clinical trials: INB-200, for the treatment of newly diagnosed glioblastoma, or GBM, and INB-100, for the treatment of patients with leukemia that are undergoing hematopoietic bone marrow transplantation. Our platform has yielded a broad portfolio of preclinical and discovery-stage programs, focused on addressing solid tumors.

The DeltEx Platform

Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. These cells serve as a functional bridge between innate and adaptive immunity to contribute to direct tumor killing as well as immune cell recruitment and activation to drive deeper immune responses. The pivotal role of gamma-delta T cells in immune function and activation, against diseases such as cancer, underscores their therapeutic potential across a wide range of solid and hematologic malignancies. We develop ex vivo expanded and activated gamma-delta T cell based upon our deep expertise in gamma-delta T cell biology, proprietary genetic engineering and cell-type specific manufacturing capabilities, collectively known as our DeltEx platform.

A Strategic Vision

We are dedicated to leveraging our DeltEx platform to develop next generation cell therapies that we believe can dramatically improve outcomes for cancer patients. We have assembled a team of experts in the discovery and development of gamma-delta T cell based therapies. We are led by William Ho, our founder and Chief Executive Officer, who has over 20 years of combined experience in the management of biotechnology companies and healthcare finance and investing. Our scientific founder and Chief Scientific Officer, Dr. Lawrence Lamb, is a pioneer in the field of gamma-delta T cell biology and manufacturing, who published the foundational work that identified the potential antileukemic effect of these cells and their association with improved overall survival. Dr. Lamb’s expertise has directed the development of our DeltEx platform and he leads our Scientific Advisory Board, which includes a globally renowned group of clinicians, oncologists and immunologists.
If you have further questions, you are welcome to contact us at: 
info@IN8bio.com

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram